SB-699551

SB-699551 is a drug that acts as a potent and selective antagonist for the 5-HT5A receptor. It was the first selective 5-HT5A antagonist developed and has been used to further research into this still somewhat uncharacterized receptor subtype.

Pharmacology

SB-699551 is a potent and selective antagonist for the 5-HT5A receptor, with around 100x selectivity over other serotonin receptor subtypes. It has been used in scientific research to help characterize the function of the 5-HT5A receptor, and has been shown to produce antidepressant effects in animal studies.

Chemistry

SB-699551 is a phenylpiperazine derivative, and is structurally related to the atypical antipsychotic drug clozapine. It was developed by the pharmaceutical company GlaxoSmithKline.

Research

Research into the 5-HT5A receptor has been limited by the lack of selective ligands, and SB-699551 has therefore been a useful tool in this area. Studies have suggested that 5-HT5A receptors may be involved in the regulation of mood, and that antagonists of this receptor may have potential as novel antidepressants.

See also

• 5-HT receptor
• Serotonin antagonist

References

SB-699551 Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.

Translate to: East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski